Editas Medicine, Inc.
EDIT · NASDAQ
Market closed$2.98$0.100000 (+3.47%)After hours $2.97 · -0.34%
Key statistics
Previous close$2.88
Open$2.79
Day high$3.03
Day low$2.77
52-week high$4.54
52-week low$1.66
Market cap291.74M
Volume1.74M
Average volume2.51M
P/E ratio-2.42
Forward P/E—
EPS-1.23
Dividend yield0.00%
Market context
Why it moved
EDIT edged higher as biotech and gene-editing stocks attracted modest buying interest amid a broader market sell-off driven by chip stock weakness, with investors rotating into select healthcare names seen as insulated from AI spending concerns and geopolitical-driven tech volatility.
What is happening
Recent company-specific developments and publisher coverage.
ad-hoc-news.de · July 17, 2026Editas Medicine stock steadies as gene-editing pipeline advances after Q1 loss narrowsQuiver Quantitative · May 26, 2026Editas Medicine Announces Promising Preclinical Results for EDIT-401, Showcasing Significant Reductions in LDL-C, Lp(a), and ApoB | EDIT Stock NewsInvesting.com · May 26, 2026Editas Medicine launches public offering of stock and warrantsStock Titan · May 26, 2026Editas offering links warrant window to cholesterol trial resultsGlobeNewswire · April 27, 2026Editas Medicine to Present New Preclinical DataEuropean Pharmaceutical Review · April 2, 2026Editas Medicine’s gene-edited therapy reni-cel sees early clinical success Mt Newswire · May 26, 2026Editas Medicine Prices Public Offering of Shares, Warrants Benzinga · May 26, 2026Editas Medicine Prices $125M Public Offering Of 55.6M Shares And Warrants At $2.25 Each Mt Newswire · May 26, 2026Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell Benzinga · May 26, 2026Editas Medicine Launches Public Stock Offering to Raise Capital Benzinga · May 26, 2026Editas Reports Cholesterol-Lowering Results for Experimental Gene Therapy Mt Newswire · May 14, 2026Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study Benzinga · May 14, 2026Editas Medicine Announces New Preclinical Data Supporting Continued Advancement Of Its In Vivo Development Candidate, EDIT-401, And Its Potential As A One-Time Treatment For Hyperlipidemia Benzinga · May 5, 2026Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $4